Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (Adpkd)
regulus therapeutics 宣佈完成第四隊列的 Rgls8429 用於治療常染色體顯性多囊腎病患者的 10億遞增劑量 (Mad) 臨床試驗招募